Inhibition of 37/67kDa Laminin-1 Receptor Restores APP Maturation and Reduces Amyloid-β in Human Skin Fibroblasts from Familial Alzheimer’s Disease
暂无分享,去创建一个
A. Lavecchia | V. D’Argenio | A. Izzo | Nunzia Mollo | D. Sarnataro | F. Margheri | G. Minopoli | F. Napolitano | N. Montuori | A. Mocali | Antaripa Bhattacharya | Federica Di Maggio | Adriana Limone | Alessandra Lo Bianco
[1] L. Buée,et al. Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer’s disease models and human brains , 2020, Acta Neuropathologica.
[2] A. Conti,et al. Targeting Mitochondrial Network Architecture in Down Syndrome and Aging , 2020, International journal of molecular sciences.
[3] V. D’Argenio,et al. New Insights into the Molecular Bases of Familial Alzheimer’s Disease , 2020, Journal of personalized medicine.
[4] A. Lavecchia,et al. APP Maturation and Intracellular Localization Are Controlled by a Specific Inhibitor of 37/67 kDa Laminin-1 Receptor in Neuronal Cells , 2020, International journal of molecular sciences.
[5] F. Perez,et al. Distinct anterograde trafficking pathways of BACE1 and amyloid precursor protein from the TGN and the regulation of amyloid-β production , 2019, Molecular biology of the cell.
[6] V. D’Argenio,et al. Microbiome Influence in the Pathogenesis of Prion and Alzheimer’s Diseases , 2019, International journal of molecular sciences.
[7] G. Cenini,et al. Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update , 2019, Front. Pharmacol..
[8] P. Gleeson,et al. The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer's disease. , 2019, Biochimica et biophysica acta. Biomembranes.
[9] P. Gleeson,et al. The trans-Golgi network is a major site for α-secretase processing of amyloid precursor protein in primary neurons , 2018, The Journal of Biological Chemistry.
[10] D. Sarnataro,et al. Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases , 2018, International journal of molecular sciences.
[11] Xian-Zhen Deng,et al. The Fate of Nascent APP in Hippocampal Neurons: A Live Cell Imaging Study. , 2018, ACS chemical neuroscience.
[12] Linfu Li,et al. The Key Roles of GSK-3β in Regulating Mitochondrial Activity , 2017, Cellular Physiology and Biochemistry.
[13] Anna Ochałek,et al. Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation , 2017, Alzheimer's Research & Therapy.
[14] Sangyun Jeong,et al. Molecular and Cellular Basis of Neurodegeneration in Alzheimer’s Disease , 2017, Molecules and cells.
[15] Weihong Song,et al. Modifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease , 2017, Front. Mol. Neurosci..
[16] F. Esposito,et al. Regulation of sub-compartmental targeting and folding properties of the Prion-like protein Shadoo , 2017, Scientific Reports.
[17] C. Procaccini,et al. Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells , 2017, Human molecular genetics.
[18] F. Checler,et al. Localization and Processing of the Amyloid-β Protein Precursor in Mitochondria-Associated Membranes , 2016, Journal of Alzheimer's disease : JAD.
[19] R. Scarpulla,et al. Concerted Action of PGC-1-related Coactivator (PRC) and c-MYC in the Stress Response to Mitochondrial Dysfunction* , 2016, The Journal of Biological Chemistry.
[20] P. Gleeson,et al. Dysregulation of intracellular trafficking and endosomal sorting in Alzheimer's disease: controversies and unanswered questions. , 2016, The Biochemical journal.
[21] C. Broeckhoven,et al. Molecular genetics of early-onset Alzheimer's disease revisited , 2016, Alzheimer's & Dementia.
[22] A. Lavecchia,et al. The 37/67kDa laminin receptor (LR) inhibitor, NSC47924, affects 37/67kDa LR cell surface localization and interaction with the cellular prion protein , 2016, Scientific Reports.
[23] M. Little,et al. LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.
[24] A. Lavecchia,et al. Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion , 2015, Oncotarget.
[25] Eloise Ferreira,et al. Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer’s disease , 2015, Expert opinion on therapeutic patents.
[26] A. Zagari,et al. Membrane protein 4F2/CD98 is a cell surface receptor involved in the internalization and trafficking of human β-Defensin 3 in epithelial cells. , 2015, Chemistry & biology.
[27] C. Seah,et al. The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid , 2014, Molecular Brain.
[28] M. Little,et al. The 37kDa/67kDa Laminin Receptor acts as a receptor for Aβ42 internalization , 2014, Scientific Reports.
[29] B. Loos,et al. High Resolution Imaging Study of Interactions between the 37 kDa/67 kDa Laminin Receptor and APP, Beta-Secretase and Gamma-Secretase in Alzheimer's Disease , 2014, PloS one.
[30] V. Boddi,et al. Altered Proteolysis in Fibroblasts of Alzheimer Patients with Predictive Implications for Subjects at Risk of Disease , 2014, International journal of Alzheimer's disease.
[31] E. Koo,et al. Activity-Induced Convergence of APP and BACE-1 in Acidic Microdomains via an Endocytosis-Dependent Pathway , 2013, Neuron.
[32] D. Chan. Fusion and fission: interlinked processes critical for mitochondrial health. , 2012, Annual review of genetics.
[33] C. Haass,et al. Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.
[34] B. Strooper,et al. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.
[35] P. Reddy,et al. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. , 2011, Human molecular genetics.
[36] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[37] Simon Lovestone,et al. The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.
[38] M. Beal,et al. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.
[39] A. Sporbert,et al. SorLA/LR11 Regulates Processing of Amyloid Precursor Protein via Interaction with Adaptors GGA and PACS-1* , 2007, Journal of Biological Chemistry.
[40] H. Anandatheerthavarada,et al. Amyloid Precursor Protein and Mitochondrial Dysfunction in Alzheimer's Disease , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[41] K. Leroy,et al. Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration , 2007, Neuropathology and applied neurobiology.
[42] F. Cordelières,et al. A guided tour into subcellular colocalization analysis in light microscopy , 2006, Journal of microscopy.
[43] B. Hyman,et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] Robert S. Balaban,et al. Mitochondria, Oxidants, and Aging , 2005, Cell.
[45] Anthony Holland,et al. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain , 2004, The European journal of neuroscience.
[46] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[47] D. Teplow,et al. Apical Sorting of β-Secretase Limits Amyloid β-Peptide Production* , 2002, The Journal of Biological Chemistry.
[48] A. Nunomura,et al. Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.
[49] H. Braak,et al. Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes , 1999 .
[50] G. P. Connolly. Fibroblast models of neurological disorders: fluorescence measurement studies. , 1998, Trends in pharmacological sciences.
[51] D. Alkon,et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[52] E. Braak,et al. Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain , 1997, Journal of neuropathology and experimental neurology.
[53] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[54] M. Trabucchi,et al. Peripheral cells as an investigational tool for Alzheimer's disease. , 1996, Life sciences.
[55] H. Wiśniewski,et al. High levels of amyloid-beta protein from S182 (Glu246) familial Alzheimer's cells. , 1995, Neuroreport.
[56] G. Schellenberg,et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.
[57] D. Pollen,et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.
[58] B. Winblad,et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[59] C. Zurzolo,et al. Cell Biology of Prion Protein. , 2017, Progress in molecular biology and translational science.
[60] D. Teplow,et al. Apical sorting of beta-secretase limits amyloid beta-peptide production. , 2002, The Journal of biological chemistry.
[61] C. Haass,et al. Posttranslational modifications of amyloid precursor protein : ectodomain phosphorylation and sulfation. , 2000, Methods in molecular medicine.
[62] H. Braak,et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. , 1999, Journal of neuropathology and experimental neurology.
[63] J. Hardy,et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.